USP 797 - Assigning Beyond-Use Dates to Compounded Sterile Preparatio

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/14

encourage image

There's no tags or description

Looks like no tags are added yet.

15 Terms

1
New cards

BUDS and expiration dates

expiration date:

  • assigned by manufacturers of conventionally manufactured products and components such as active pharmaceutical ingredients (APIs)

  • expressed as either a specific month in a specific year or a specific day of the month in a specific year

  • the time during which a product can be expected to meet the requirements of the compendial monograph, or maintain expected quality provided it is kept under the specified storage conditions

  • limits the time during which the conventionally manufactured product, API, or added substance may be dispensed or used

  • assigned by manufacturers based on analytical and performance testing and packaging integrity of the product

  • specific for a particular formulation in its container and at stated exposure and storage conditions (i.e., illumination, temperature)

beyond-use date:

  • assigned to compounded preparations

  • the date, or the hour and date, beyond which the preparation must not be used and must be discarded

  • determined from the date/time that preparation is initiated

  • not intended to limit the time during which the CSP is administered


2
New cards

knowledge check


3
New cards

factors to consider when establishing a BUD

factors to consider when assigning BUDs to CSPs:

  • chemical and physical properties of the components and the container closure system

  • environment where the CSP is prepared

  • whether nonsterile ingredients have been used to prepare the CSP

  • sterilization method

  • whether or not sterility testing has been performed

  • intended storage temperature for the finished CSP


4
New cards

assigning BUDs—stability

oxidation and hydrolysis are reactions that can be identified by light, heat, or the presence of water, which can reflect the stability of medications

other factors to consider regarding stability when assigning BUDs:

  • physical and chemical stability of the active ingredients and added substances in a CSP

  • the effects of light, heat, and water on dehydration of the CSP

  • materials of composition of the container closure system and the compatibility of the container closure system that will be used for the final CSP to prevent leaching or sorption

  • the ability of the container closure system to withstand intended storage conditions (e.g., freezing)


5
New cards

assigning BUDs—sterility considerations

immediate use

  • environment: uncontrolled environment with no primary engineering control (PEC)

  • BUD limit: 4 hours at any storage condition

category 1

  • environment: ISO class 5 PEC placed in unclassified environment

  • BUD limit: 12 hours controlled room temperature, 24 hours refrigerated

category 2

  • environment: ISO class 5 PEC placed in an ISO class 7 buffer room

  • BUD limits: 1 to 45 days controlled room temperature, 4 to 60 days refrigerated, 45 to 90 days frozen

category 3

  • environment: ISO class 5 PEC placed in an ISO class 7 buffer room

  • additional facility and personnel requirements:

  • BUD limits: 60 to 90 days controlled room temperature, 90 to 120 days refrigerated, 120 to 180 days frozen


6
New cards

how factors impact length of assigned BUDs

nonsterile components

  • impact: shortens BUD for category 2 CSPs

  • nonsterile ingredients increase the risk of contamination or failure to achieve sterility

  • example:

    • BUDs for category 2 CSPs that (1) are aseptically processed. (2) are stored at controlled room temperature, and (3) have not undergone or passed sterility testing

terminal sterilization vs aseptic processing

  • impact: terminal sterilization lengthens BUD for category 2 and category 3 CSPs

  • using a verified method of terminal sterilization (e.g., auto-claving, dry heat sterilization) provides reasonable assurance that a CSP will be sterile. aseptic processing (e.g., filtration or using only conventionally manufactured sterile products as components) is more difficult to verify for

sterility testing

  • impact: lengthens BUD for category 2 CSPs

  • sterility testing provides reasonable assurance (but does not guarantee) sterility has been achieved

  • example

    • BUDs for category 2 CSPs that are (1) terminally sterilized and (2) stored at controlled room temperature:

      • did not undergo and pass sterility testing: 14 days

      • passed sterility testing: 45 days

storage conditions

  • impact: colder temperatures lengthen BUD for category 2 and category 3 CSPs

  • USP <659> packaging and storage requirements explains that colder temperatures slow the growth of most microorganisms refrigerated or frozen CSPs have longer BUDs than do those CSPs stored at room temperature — provided that the CSP and its container


7
New cards

knowledge check


8
New cards

establishing BUDs for different categories of CSPs

USP <797> lists three tables to enable compounding professionals to assign an appropriate BUD to CSPs and lists caveats for use of the tables. the assigned BUD for any CSP may not exceed:

  • the expiration date or remaining BUD of any of its individual components

  • the known duration for physical and chemical stability of the CSP

  • exception: some BUDs may exceed the BUD of the compounded components if the physical, chemical, and microbiological quality is not negatively affected (e.g., pH altering solutions)

table 12

table 13

table 14


9
New cards

establishing BUDs for category 3 CSPs

category 3 CSPs have additional requirements to address the additional risks from increasing storage times:

  • personal compounding category 3 CSPs must complete garbing competency and aseptic manipulation every 3 months, instead of every 6 months for category 2 CSPs

  • personnel must adhere to stricter garbing requirements, such as using sterile garb without any exposed skin

  • viable air sampling must be performed monthly and surface sampling performed weekly

  • additional surface sampling of the PEC must be performed after compounding a category 3 CSP

  • the use of sporicidal disinfectants in the PEC and work surfaces outside the PEC must be completed weekly


10
New cards

establishing BUDs for category 3 CSPs—addtional requirements

further requirements for category 3 CSPs to address additional risks:

  • require stability information using a stability indicating method that can distinguish the active ingredient from its degradants and impurities and quantify the amount of the active ingredient

    • may be performed by the compounder or obtained through third-party sources

    • must be the exact same formulation (bracketing acceptable)

    • CSP must be packaged and stored in a container closure of the same materials of composition as that used in the study

    • container closure system must be tested once per formulation

    • particulate testing must occur once per formulation for injectables and ophthlamics

  • release testing each time category 3 CSPs are prepared

    • sterility testing (see USP <71>)

  • endotoxin testing, if required based on dosage form


11
New cards

knowledge check part 1


12
New cards

knowledge check part 2


13
New cards

multiple-dose CSPs

compounded aqueous multiple-dose containers:

  • have more than one dose

  • are intended to be entered or penetrated multiple times

  • usually contain a preservative

    • if present, the preservative must be compatible with the CSP and route of administration

  • may be prepared only in a cleanroom suite

  • must be discarded on the assigned BUD or 28 days after initial puncture, whichever is shorter

  • must pass a container closure integrity test (USP <1207> package integrity evaluation—sterile products)

    • performed once initially for that volume of CSP in the specific container closure system to be dispensed

  • must demonstrate ability to pass USP <51> antimicrobial effectiveness testing

  • there is an exception for multiple-dose nonpreserved aqueous topical and topical ophthalmic CSPs

    • these CSPs do not require a USP <51> test if:

      • they are prepared as a category 2 or category 3

      • they are used by a single patient

      • they are labeled (in a label or labeling) to indicate that once opened, it must be discarded 24 hours after opening when stored at room temperature and/or that once opened, it must be discarded 72 hours after opening when stored under refrigeration


14
New cards

antimicrobial effectiveness testing

options for compounding professionals to obtain evidence to support antimicrobial effectiveness in multiple-dose CSPs:

  • perform or contract for testing once for each formulation in the particular container closure system in which it will be packaged

  • reference antimicrobial effectiveness testing results provided by an FDA-registered facility (e.g., contract testing laboratory) or published in peer-reviewed literature sources

    • CSP formulation, including any preservative, and container closure system are exactly the same as those tested

  • perform or reference a bracketing study on a low concentration and a high concentration of the active ingredient in the formulation to establish preservative effectiveness across various strengths of the same formulation

    • the concentration of all other ingredients, including preservatives, must be the same throughout the bracketing study

multiple-dose CSPs are different than compounded stock solutions, which do not undergo the aforementioned testing

15
New cards

knowledge check